Marker Therapeutics, Inc.

📢 Today we reported our second quarter 2024 financial results and provided business updates. Follow the link for more information: https://lnkd.in/gDjQfatn #multiTAA #immunotherapy #ClinicalTrials #CellTherapy #patients #cancer #biotech #lymphoma #AML #PancreaticCancer

NEWS 💥 NEWS 💥 NEWS! Marker Therapeutics was awarded a $2 million grant from the #NIH Small Business Innovation Research (#SBIR) program! ✨ The proceeds of this award will support our Phase 1 APOLLO study, investigating the #safety and #efficacy of MT-601 in patients with non-Hodgkin’s lymphoma who have relapsed following anti-CD19 CAR-T cell therapy. For more information: https://lnkd.in/gHPjgKUf #immunotherapy #CART #multiTAA #ClinicalTrials #CellTherapy #lymphoma #patients #cancer #biotech

Today we announced that Dr. Shouse, the Principal Investigators at City of Hope, was invited to present his experience from our clinical study in patients with #lymphoma (APOLLO study) at the 11th Global Summit on Hematologic Malignancies.   Marker’s Phase 1 #APOLLO study is investigating MT-601, a #multiTAA-specific T cell product, for the treatment of patients with #lymphoma who have #relapsed or are #ineligible to receive #CAR T cell therapy.   Key Highlights: 🌟 Three patients were treated at City of Hope as part of the #APOLLO study. 🌟 First study participant treated with MT-601 had diffuse large B cell lymphoma (DLBCL) and failed 4 prior lines of therapy, including a relapse within 90 days of CAR T cell therapy. This participant achieved a #CompleteResponse 8 weeks after the second infusion of MT-601 and remains in complete response #9 #months after initial treatment with MT-601. 🌟 Another study participant was diagnosed with follicular lymphoma that transformed into DLBCL. This participant failed 12 lines of therapy, including CAR T cells. 8 weeks after treatment with MT-601, the study participant achieved a #CompleteResponse, which is maintained 3 months following initial treatment with MT-601. 🌟 The third study participant treated at City of Hope had DLBCL with cutaneous involvement and was not eligible for CAR T cell therapy. This participant achieved a #PartialResponse 8 weeks after MT-601 treatment with all lesions decreasing in size including one that has completely resolved.   🌟 Treatment was well tolerated among all patients with no significant treatment-related adverse events.     For more information: https://lnkd.in/gVgUburj    #immunotherapy #CART #multiTAA #ClinicalTrials #CellTherapy #lymphoma #patients #cancer #biotech

Join our CEO Juan Vera and learn more about Marker’s #multiTAA T cell products and clinical studies. 📅 Date: March 26, 2024 ⏰ Time: 10:00 AM, EDT Don’t miss out! Your virtual seat awaits here: https://lnkd.in/dx_JUSBm During the conference, our team will conduct one-on-one meetings with registered investors to discuss clinical developments, recent achievements, and anticipated milestones.   For more information: https://lnkd.in/gkC_h5Uf   #immunotherapy #ClinicalTrials #CellTherapy #patients #cancer #biotech #lymphoma #AML #PancreaticCancer

We are thrilled to present at the H.C. Wainwright & Co., LLC 2nd Annual Cell Therapy Virtual Conference on March 26, 2024! Join our CEO Juan Vera and learn more about Marker’s #multiTAA T cell products and clinical programs. 📅 Date: March 26, 2024 🕙 Time: 10:00 AM, EDT 👉 Register here: https://lnkd.in/dSQTZqkm The presentation will be available for replay starting March 26, 2024 on the Company’s IR website under Events & Presentations. During the conference, our team will conduct one-on-one meetings with registered investors to discuss clinical development, recent achievements, and anticipated milestones.  For more information: https://lnkd.in/gkC_h5Uf   #immunotherapy #ClinicalTrials #CellTherapy #patients #cancer #biotech #lymphoma #AML #PancreaticCancer

💥 Breaking News! Today we announced that the United States Adopted Names (#USAN) Council and the World Health Organization (#WHO) International Nonproprietary Names (#INN) expert committee approved “neldaleucel” as the nonproprietary (generic) name for MT-601, our #multiTAA-specific T cell product candidate for the treatment of patients with #lymphoma. Follow the link for more information: https://lnkd.in/gnjjXXvB #immunotherapy #ClinicalTrials #CellTherapy #patients #cancer #biotech

📢 Exciting News!   Today we announced clinical program updates!   Key Highlights: 🌟 Strategic prioritization of clinical programs with a focus on MT-601 in CAR relapse patients with #lymphoma based on promising non-clinical and clinical data. 🌟 Promising clinical observations and new directions with MT-401 in patients with #MRD (measurable residual disease) in #AcuteMyeloidLeukemia (AML).   For more information click here: https://lnkd.in/gKyPUKeN   #immunotherapy #multiTAA #ClinicalTrials #CellTherapy #patients #cancer #biotech #PancreaticCancer

Meet us in San Francisco during J.P. Morgan week from January 8-10! We are excited to kick off the new year with #JPM! ✨ If you are attending #JPM2024 and want to connect with our team, please contact us. #SanFrancisco #multiTAAs #biotech #innovation #cancer #immunotherapy #AML #lymphoma #healthcare

We are honored to be recognized as part of the 2023 FreeMind Elite! 🌟 The FreeMind Elite is a selection of FreeMind Group clients who have excelled in securing non-dilutive funding and developing medical technologies in the life sciences sector over the past year. Thank you FreeMind Group for this recognition and our existing partnership! 🎉🙌 #FreeMindElite #immunotherapy #multiTAA #ClinicalTrials #CellTherapy #lymphoma #AML #patients #cancer #biotech

📢 Exciting News! ✨ Our first patient with #lymphoma treated with MT-601 remains in complete response! ✨   Today we announced an important milestone in our ongoing Phase 1 APOLLO study investigating MT-601 in patients with #lymphoma: Our first study participant with Non-Hodgkin’s Lymphoma who relapsed after CAR T cell therapy remains in complete response 6 months after MT-601 treatment! 🎉   Key Highlights: 🌟 Study participant failed 4 prior lines of therapy, including a relapse within 90 days after anti-CD19 CAR T cell therapy 🌟 Subsequent treatment with 2 doses of MT-601 was well tolerated without treatment-related adverse events 🌟 Patient achieved complete response 8 weeks after second dose of MT-601 🌟 Complete response was maintained for at least 6 months, suggesting that MT-601 is more durable compared to CAR T cells in this study participant   Read the full story here: https://lnkd.in/gDPFQKtf     MT-601 is a multi-tumor associated antigen (#multiTAA)-specific T cell product, designed to selectively amplify tumor-specific T cells to recognize a wide spectrum of tumor antigens. multiTAAs are non-genetically modified T cell therapies that have shown excellent tolerability and a favorable safety profile in clinical studies.   #immunotherapy #cartcelltherapy #multiTAA #ClinicalTrials #CellTherapy #lymphoma #patients #cancer #biotech